rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase.
|
28068330 |
2017 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Leukaemia</span> arising in a JAK2 V617F</span>-negative clone is TP53 independent and shows better survival.
|
28542718 |
2017 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
In mice, tamoxifen treatment blocked development of JAK2(V617F)-induced myeloproliferative neoplasm in vivo, induced apoptosis of human JAK2(V617F+) HSPCs in a xenograft model, and sensitized MLL-AF9(+) leukemias to chemotherapy.
|
25479752 |
2014 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs).
|
21326037 |
2011 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.
|
21712540 |
2011 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01).
|
17229652 |
2007 |
rs77375493
|
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Homozygous V617F mutation is associated with the clinical picture of classic PV and with a higher tendency to secondary myelofibrosis, but with no increased leukemia unless other biological or genetic factors come into play, such as myelosuppressive agents or the acquisition of additional biologic or genetic defects.
|
16810614 |
2006 |